keyword
MENU ▼
Read by QxMD icon Read
search

ACE inhibitors and ARBS

keyword
https://www.readbyqxmd.com/read/28426793/prevalence-of-cardiovascular-medication-on-secondary-prevention-after-myocardial-infarction-in-china-between-1995-2015-a-systematic-review-and-meta-analysis
#1
Min Zhao, Kerstin Klipstein-Grobusch, Xin Wang, Johannes B Reitsma, Dong Zhao, Diederick E Grobbee, Ian Graham, Ilonca Vaartjes
BACKGROUND: Myocardial Infarction (MI) has become a major cause of morbidity and mortality in China, but little is known about the prevalence of guideline-recommended cardiovascular medications after MI events over the last two decades. This systematic review and meta-analysis aims to summarize cardiovascular medication use between 1995-2015 and to assess factors in associated with the trends in cardiovascular medications. METHOD: A systematic search was conducted in four databases (Pubmed, Embase, CENTRAL, and CNKI) to obtain observational studies published between 1995 and 2015, reporting on the use of cardiovascular medications in China...
2017: PloS One
https://www.readbyqxmd.com/read/28416734/the-angiotensin-receptor-blocker-losartan-inhibits-mammary-tumor-development-and-progression-to-invasive-carcinoma
#2
Rhiannon Coulson, Seng H Liew, Angela A Connelly, Nicholas S Yee, Siddhartha Deb, Beena Kumar, Ana C Vargas, Sandra A O'Toole, Adam C Parslow, Ashleigh Poh, Tracy Putoczki, Riley J Morrow, Mariah Alorro, Kyren A Lazarus, Evie F W Yeap, Kelly L Walton, Craig A Harrison, Natalie J Hannan, Amee J George, Colin D Clyne, Matthias Ernst, Andrew M Allen, Ashwini L Chand
Drugs that target the Renin-Angiotensin System (RAS) have recently come into focus for their potential utility as cancer treatments. The use of Angiotensin Receptor Blockers (ARBs) and Angiotensin-Converting Enzyme (ACE) Inhibitors (ACEIs) to manage hypertension in cancer patients is correlated with improved survival outcomes for renal, prostate, breast and small cell lung cancer. Previous studies demonstrate that the Angiotensin Receptor Type I (AT1R) is linked to breast cancer pathogenesis, with unbiased analysis of gene-expression studies identifying significant up-regulation of AGTR1, the gene encoding AT1R in ER+ve/HER2-ve tumors correlating with poor prognosis...
March 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28399844/implementation-of-a-pragmatic-randomized-trial-of-screening-for-chronic-kidney-disease-to-improve-care-among-non-diabetic-hypertensive-veterans
#3
Carmen A Peralta, Martin Frigaard, Anna D Rubinsky, Leticia Rolon, Lowell Lo, Santhi Voora, Karen Seal, Delphine Tuot, Shirley Chao, Kimberly Lui, Phillip Chiao, Neil Powe, Michael Shlipak
BACKGROUND: Whether screening for chronic kidney disease (CKD) can improve the care of persons at high risk for complications remains uncertain. We describe the design and early implementation experience of a pilot, cluster-randomized pragmatic trial to evaluate the feasibility, implementation, and effectiveness of a "triple marker" CKD screening program (creatinine, cystatin C and albumin to creatinine ratio) for improving care among hypertensive veterans seen in primary care at one Veterans Administration Hospital...
April 12, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28395659/abelmoschus-manihot-a-traditional-chinese-medicine-versus-losartan-potassium-for-treating-iga-nephropathy-study-protocol-for-a-randomized-controlled-trial
#4
Ping Li, Yi-Zhi Chen, Hong-Li Lin, Zhao-Hui Ni, Yong-Li Zhan, Rong Wang, Hong-Tao Yang, Jing-Ai Fang, Nian-Song Wang, Wen-Ge Li, Xue-Feng Sun, Xiang-Mei Chen
BACKGROUND: IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide, but effective therapy remains limited and many patients progress to end-stage renal disease (ESRD). Only angiotensin-converting enzyme inhibitors (ACE-I)/angiotensin-receptor blockers (ARB) show a high level of evidence (1B level) of being of value in the treatment for IgAN according to the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. However, traditional Chinese medicine has raised attention in kidney disease research...
April 11, 2017: Trials
https://www.readbyqxmd.com/read/28389482/what-are-the-risks-and-benefits-of-temporarily-discontinuing-medications-to-prevent-acute-kidney-injury-a-systematic-review-and-meta-analysis
#5
Penny Whiting, Andrew Morden, Laurie A Tomlinson, Fergus Caskey, Thomas Blakeman, Charles Tomson, Tracey Stone, Alison Richards, Jelena Savović, Jeremy Horwood
OBJECTIVES: To summarise evidence on temporary discontinuation of medications to prevent acute kidney injury (AKI). DESIGN: Systematic review and meta-analysis of randomised and non-randomised studies. PARTICIPANTS: Adults taking diuretics, ACE inhibitors (ACEI), angiotensin receptor blockers (ARB), direct renin inhibitors, non-steroidal anti-inflammatories, metformin or sulfonylureas, experiencing intercurrent illnesses, radiological or surgical procedures...
April 7, 2017: BMJ Open
https://www.readbyqxmd.com/read/28384014/cardiac-medication-use-in-patients-with-acute-myocardial-infarction-and-nonobstructive-coronary-artery-disease
#6
Falisha Adatia, Shannon Galway, Maja Grubisic, May Lee, Patrick Daniele, Karin H Humphries, Tara L Sedlak
IMPORTANCE: Patients with acute myocardial infarction (MI) and nonobstructive coronary artery disease (CAD) have an elevated cardiac event rate, suggesting that these patients may benefit from cardiac medication. OBJECTIVE: We evaluated the rates of cardiac medication use 3 months before angiography and 3 months following clinically indicated angiography for MI in patients with no CAD, nonobstructive CAD, and obstructive CAD. We also examined the sex differences in cardiac medication use 3 months following angiography in patients by extent of angiographic CAD...
April 6, 2017: Journal of Women's Health
https://www.readbyqxmd.com/read/28384013/sex-differences-in-cardiac-medication-use-post-catheterization-in-patients-undergoing-coronary-angiography-for-stable-angina-with-nonobstructive-coronary-artery-disease
#7
Shannon Galway, Falisha Adatia, Maja Grubisic, May Lee, Patrick Daniele, Karin H Humphries, Tara L Sedlak
BACKGROUND: Treatment of patients with stable angina and nonobstructive coronary artery disease (CAD) has not been well characterized. We comparatively evaluated medication use in males and females with stable angina with no CAD, nonobstructive CAD, and obstructive CAD. METHODS: We studied all patients ≥20 years old with stable angina undergoing coronary angiography in British Columbia (BC), Canada, from January 2008 to March 2010 (n = 7,535). No CAD, nonobstructive CAD, and obstructive CAD were defined as 0%, 1%-49%, and ≥50% luminal narrowing in any epicardial coronary artery, respectively...
April 6, 2017: Journal of Women's Health
https://www.readbyqxmd.com/read/28379619/blood-pressure-lowering-efficacy-of-renin-inhibitors-for-primary-hypertension
#8
REVIEW
Vijaya M Musini, Kendra Ak Lawrence, Patricia M Fortin, Ken Bassett, James M Wright
BACKGROUND: Hypertension is a chronic condition associated with an increased risk of mortality and morbidity. Renin is the enzyme responsible for converting angiotensinogen to angiotensin I, which is then converted to angiotensin II. Renin inhibitors are a new class of drugs that decrease blood pressure (BP) by preventing the formation of both angiotensin I and angiotensin II. OBJECTIVES: To quantify the dose-related BP lowering efficacy of renin inhibitors compared to placebo in the treatment of primary hypertension...
April 5, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28375400/clinical-inquiry-do-ace-inhibitors-or-arbs-help-prevent-kidney-disease-in-patients-with-diabetes-and-normal-bp
#9
Gregory S Trietley, Stephen A Wilson, Parul Chaudhri, Nicole Payette, Ashley Higbea, Joan Nashelsky
Yes for angiotensin-converting enzyme (ACE) inhibitors, no for angiotensin receptor blockers (ARBs). A 2011 meta-analysis of 5 RCTs (total 2975 patients) that compared ACE inhibitor therapy with placebo in diabetic patients without hypertension and albuminuria found that ACE inhibitors reduced the risk of new-onset microalbuminuria or macroalbuminuria by 18% (relative risk [RR]=0.82; 95% confidence interval [CI], 0.73-0.92).
April 2017: Journal of Family Practice
https://www.readbyqxmd.com/read/28340535/continuation-of-renin-angiotensin-aldosterone-inhibitors-does-not-impact-renal-function-among-patients-undergoing-percutaneous-nephrolithotomy
#10
Nishant Patel, Benjamin R Cohen, Shubha De, Ganesh Kartha, Ina Li, Carl Sarkissian, Juan Calle, Manoj Monga
OBJECTIVE: In the perioperative period, renin-angiotensin-aldosterone system (RAAS) inhibitors may result in cardiovascular and renal functional changes. We sought to determine the acute and chronic renal functional and blood pressure effects of continuing or withdrawing angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) after percutaneous nephrolithotomy (PCNL). MATERIALS AND METHODS: This was a retrospective review of all patients undergoing PCNL at our institution from 2002 to 2013...
April 20, 2017: Journal of Endourology
https://www.readbyqxmd.com/read/28332417/cost-effectiveness-of-angiotensin-converting-enzyme-inhibitors-versus-angiotensin-ii-receptor-blockers-as-first-line-treatment-in-autosomal-dominant-polycystic-kidney-disease
#11
L A Clark, S Whitmire, S Patton, C Clark, C M Blanchette, R Howden
INTRODUCTION: Autosomal dominant polycystic kidney disease (ADPKD) is a rare kidney disorder impacting approximately 1:2500 individuals among the general US population. Hypertension is a significant predictor of ADPKD progression and risk factor for development of cardiovascular disease (CVD), the most common cause for mortality among ADPKD patients. Angiotensin-converting enzymes inhibitors (ACE-I) are widely used as first-line treatment in ADPKD for the management of hypertension. However, their cost-effectiveness relative to other hypertensive medications, such as angiotensin II receptor blockers (ARB) has never been assessed...
March 23, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28329163/determinants-and-clinical-outcome-of-uptitration-of-ace-inhibitors-and-beta-blockers-in-patients-with-heart-failure-a-prospective-european-study
#12
W Ouwerkerk, A A Voors, S D Anker, J G Cleland, K Dickstein, G Filippatos, P van der Harst, H L Hillege, C C Lang, J M Ter Maaten, L L Ng, P Ponikowski, N J Samani, D J van Veldhuisen, F Zannad, M Metra, A H Zwinderman
Introduction: Despite clear guidelines recommendations, most patients with heart failure and reduced ejection-fraction (HFrEF) do not attain guideline-recommended target doses. We aimed to investigate characteristics and for treatment-indication-bias corrected clinical outcome of patients with HFrEF that did not reach recommended treatment doses of ACE-inhibitors/Angiotensin receptor blockers (ARBs) and/or beta-blockers. Methods and results: BIOSTAT-CHF was specifically designed to study uptitration of ACE-inhibitors/ARBs and/or beta-blockers in 2516 heart failure patients from 69 centres in 11 European countries who were selected if they were suboptimally treated while initiation or uptitration was anticipated and encouraged...
March 11, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28321311/ace-and-response-to-pulmonary-rehabilitation-in-copd-two-observational-studies
#13
Samantha S C Kon, Caroline J Jolley, Dinesh Shrikrishna, Hugh E Montgomery, James R A Skipworth, Zudin Puthucheary, John Moxham, Michael I Polkey, William D-C Man, Nicholas S Hopkinson
INTRODUCTION: Skeletal muscle impairment is an important feature of chronic obstructive pulmonary disease (COPD). Renin-angiotensin system activity influences muscle phenotype, so we wished to investigate whether it affects the response to pulmonary rehabilitation. METHODS: Two studies are described; in the first, the response of 168 COPD patients (mean forced expiratory volume in one second 51.9% predicted) to pulmonary rehabilitation was compared between different ACE insertion/deletion polymorphism genotypes...
2017: BMJ Open Respiratory Research
https://www.readbyqxmd.com/read/28319533/-perfscore-a-multidimensional-score-a-simple-way-to-predict-the-success-of-cardiac-rehabilitation
#14
Patrizia Maras, Sara Doimo, Alessando Altinier, Alessio Della Mattia, Luigia Scudeller, Gianfranco Sinagra, Catherine Klersy
BACKGROUND: We propose a simple and reliable score, performance score ('PERFSCORE'), that allows cardiologists to assess the achievement of therapeutic goals. METHODS: We identified six indicators of cardiac rehabilitation performance: heart rate (HR) less than 70 beats/min; blood pressure (BP) less than 140/90 mmHg; smoking cessation or non-smokers; left ventricular ejection fraction (LVEF) more than 40%; LDLc less than 100 mg/dl or more than 70 mg/dl if diabetic; and on treatment at least with three drugs among angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blocker (ARBs), β-blockers, statins, and ASA...
March 17, 2017: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/28285267/angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-in-high-vascular-risk
#15
Louis Potier, Ronan Roussel, Yedid Elbez, Michel Marre, Uwe Zeymer, Christopher M Reid, Magnus Ohman, Kim A Eagle, Deepak L Bhatt, Philippe Gabriel Steg
OBJECTIVE: ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are widely prescribed in patients with high cardiovascular (CV) risk. However, whether both classes have equivalent effectiveness to prevent CV events remains unclear. The aim of this study was to compare the incidence of major CV events between ACEI and ARB users. METHODS: The Reduction of Atherothrombosis for Continued Health registry is an observational study who enrolled 69 055 individuals with high CV risk...
March 11, 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/28284756/feasibility-and-association-of-neurohumoral-blocker-up-titration-after-cardiac-resynchronization-therapy
#16
Pieter Martens, Frederik H Verbrugge, Petra Nijst, Philippe P B Bertrand, Matthias Dupont, Wilson W H Tang, Wilfried Mullens
BACKGROUND: Cardiac resynchronization therapy (CRT) improves mortality and morbidity on top of optimal medical therapy in heart failure with reduced ejection fraction (HFrEF). This study aimed to elucidate the association between neurohumoral blocker up-titration after CRT implantation and clinical outcomes. METHODS AND RESULTS: Doses of angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), and beta-blockers were retrospectively evaluated in 650 consecutive CRT patients implanted from October 2008 to August 2015 and followed in a tertiary multidisciplinary CRT clinic...
March 8, 2017: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/28271625/clinical-characteristics-of-patients-from-the-worldwide-registry-on-peripartum-cardiomyopathy-ppcm-eurobservational-research-programme-in-conjunction-with-the-heart-failure-association-of-the-european-society-of-cardiology-study-group-on-ppcm
#17
Karen Sliwa, Alexandre Mebazaa, Denise Hilfiker-Kleiner, Mark C Petrie, Aldo P Maggioni, Cecile Laroche, Vera Regitz-Zagrosek, Maria Schaufelberger, Luigi Tavazzi, Peter van der Meer, Jolien W Roos-Hesselink, Petar Seferovic, Karin van Spandonck-Zwarts, Amam Mbakwem, Michael Böhm, Frederic Mouquet, Burkert Pieske, Roger Hall, Piotre Ponikowski, Johann Bauersachs
AIMS: The purpose of this study is to describe disease presentation, co-morbidities, diagnosis and initial therapeutic management of patients with peripartum cardiomyopathy (PPCM) living in countries belonging to the European Society of Cardiology (ESC) vs. non-ESC countries. METHODS AND RESULTS: Out of 500 patients with PPCM entered by 31 March 2016, we report on data of the first 411 patients with completed case record forms (from 43 countries) entered into this ongoing registry...
March 8, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28260186/efficacy-of-zofenopril-vs-irbesartan-in-combination-with-a-thiazide-diuretic-in-hypertensive-patients-with-multiple-risk-factors-not-controlled-by-a-previous-monotherapy-a-review-of-the-double-blind-randomized-z-studies
#18
REVIEW
Stefano Omboni, Ettore Malacco, Claudio Napoli, Pietro Amedeo Modesti, Athanasios Manolis, Gianfranco Parati, Enrico Agabiti-Rosei, Claudio Borghi
Combinations between an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) and hydrochlorothiazide (HCTZ) are among the recommended treatments for hypertensive patients uncontrolled by monotherapy. Four randomized, double-blind, parallel group studies with a similar design, including 1469 hypertensive patients uncontrolled by a previous monotherapy and with ≥1 cardiovascular risk factor, compared the efficacy of a combination of a sulfhydryl ACE inhibitor (zofenopril at 30 or 60 mg) or an ARB (irbesartan at 150 or 300 mg) plus HCTZ 12...
March 4, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28258036/use-of-ace-inhibitors-and-falls-in-patients-with-parkinson-s-disease
#19
Alice Laudisio, Maria Rita Lo Monaco, Maria Caterina Silveri, Anna Rita Bentivoglio, Davide L Vetrano, Maria Stella Pisciotta, Vincenzo Brandi, Roberto Bernabei, Giuseppe Zuccalà
Falls represent a major concern in patients with Parkinson's disease (PD); however, currently acknowledged treatments for PD are not effective in reducing the risk of falling. The aim was to assess the association of use of ACE-inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) with falls among patients with PD. We analysed data of 194 elderly with PD attending a geriatric Day Hospital. Self-reported history of falls that occurred over the last year, as well as use of drugs, including ACEIs and angiotensin II receptor blockers (ARBs) were recorded...
February 22, 2017: Gait & Posture
https://www.readbyqxmd.com/read/28249992/effect-of-cost-sharing-on-adherence-to-evidence-based-medications-in-patients-with-acute-coronary-syndrome
#20
Beatriz González López-Valcárcel, Julián Librero, Aníbal García-Sempere, Luz María Peña, Sofía Bauer, Jaume Puig-Junoy, Juan Oliva, Salvador Peiró, Gabriel Sanfélix-Gimeno
OBJECTIVES: Cost-sharing scheme for pharmaceuticals in Spain changed in July 2012. Our aim was to assess the impact of this change on adherence to essential medication in patients with acute coronary syndrome (ACS) in the region of Valencia. METHODS: Population-based retrospective cohort of 10 563 patients discharged alive after an ACS in 2009-2011. We examined a control group (low-income working population) that did not change their coinsurance status, and two intervention groups: pensioners who moved from full coverage to 10% coinsurance and middle-income to high-income working population, for whom coinsurance rose from 40% to 50% or 60%...
March 1, 2017: Heart: Official Journal of the British Cardiac Society
keyword
keyword
64582
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"